Chardan Capital Markets Starts Axovant Sciences (AXON) at Sell; RVT-101 Remains Overrated
Tweet Send to a Friend
Chardan Capital starts Axovant Sciences (NYSe: AXON) with a Sell rating and $10 price target.Analyst Gbola Amusa, MD, noted that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
